Coerente Capital Management Sells 300 Shares of Becton, Dickinson and Company (NYSE:BDX)

Coerente Capital Management lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 8.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,346 shares of the medical instruments supplier’s stock after selling 300 shares during the quarter. Becton, Dickinson and Company comprises about 0.1% of Coerente Capital Management’s investment portfolio, making the stock its 29th biggest position. Coerente Capital Management’s holdings in Becton, Dickinson and Company were worth $766,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock worth $6,067,196,000 after purchasing an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier’s stock valued at $2,751,187,000 after buying an additional 3,219,317 shares during the period. Geode Capital Management LLC grew its position in Becton, Dickinson and Company by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock worth $1,437,161,000 after buying an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 15.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier’s stock worth $1,401,126,000 after buying an additional 810,345 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its position in Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock worth $1,004,132,000 after buying an additional 1,057,879 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP David Shan sold 1,166 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares of the company’s stock, valued at $783,194.25. This represents a 20.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,104 shares of company stock worth $399,675. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.0%

Shares of NYSE:BDX opened at $172.62 on Thursday. The company has a fifty day moving average of $184.21 and a 200-day moving average of $213.79. The company has a market capitalization of $49.48 billion, a PE ratio of 28.68, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Becton, Dickinson and Company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.17 earnings per share. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a yield of 2.41%. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BDX shares. Wells Fargo & Company downgraded Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. William Blair downgraded Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Morgan Stanley decreased their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Finally, Citigroup downgraded Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and decreased their price objective for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.